Effects of Electroconvulsive Therapy (ECT) in Bipolar Depression
This study has been withdrawn prior to enrollment.
(Due to a lack of participants, this study has been closed.)
Sponsor:
Mclean Hospital
Information provided by (Responsible Party):
Brian P. Brennan, MD, Mclean Hospital
ClinicalTrials.gov Identifier:
NCT01557933
First received: March 9, 2012
Last updated: November 28, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary purpose of this study is to use magnetic resonance spectroscopy (MRS) to measure the levels of several brain chemicals including, but not limited to, glutamate, glutamine, and N-acetylaspartate, before and after treatment with ECT. In addition to MRS, the investigators will use several other MRI techniques including structural MRI, resting state functional MRI (fMRI), and diffusion tensor imaging (DTI) to measure how the structure and function of the brain changes with ECT.
The investigators hypothesize that the Gln/Glu ratio is increased in the anterior cingulate cortex (ACC), but not the parieto-occipital cortex (POC), following the first ECT treatment.
| Condition | Intervention |
|---|---|
|
Bipolar Disorder |
Other: No interventions will be used |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | A Study of the Acute and Chronic Effects of Electroconvulsive Therapy on Glutamatergic Neurotransmission in Bipolar Depression |
Resource links provided by NLM:
Further study details as provided by Mclean Hospital:
Primary Outcome Measures:
- Gln/Glu ratio following the first ECT treatment [ Time Frame: Participants will undergo an MR scan within 24 hours of their first ECT treatment ] [ Designated as safety issue: No ]The Gln/Glu ratio is examined in the anterior cingulate cortex (ACC) and the parieto-occipital cortex (POC) following the first ECT treatment.
Secondary Outcome Measures:
- The Gln/Glu ratio following the sixth ECT treatment. [ Time Frame: Participants will undergo an MR scan within 24 hours of their sixth ECT treatment, which is approximately two weeks after their first ECT treatment ] [ Designated as safety issue: No ]The Gln/Glu ratio is examined in both the ACC and POC following the sixth ECT treatment.
| Enrollment: | 0 |
| Study Start Date: | April 2011 |
| Study Completion Date: | July 2012 |
| Primary Completion Date: | July 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
ECT
All study subjects have consented to receive ECT.
|
Other: No interventions will be used
No interventions will be used
|
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Twelve study participants between the ages of 18-55 with will be recruited from inpatient units at McLean Hospital.
Criteria
Inclusion Criteria:
- Male or female age 18-55
- Meets DSM-IV criteria for Bipolar Disorder Type I, II, or NOS with current episode depressed
- Has been scheduled to be evaluated by an ECT consultant from the McLean Hospital ECT service
- Current score of greater than or equal to 24 on the Montgomery-Asberg Depression Rating Scale (MADRS)
Exclusion Criteria:
- Unwillingness or inability to provide informed consent
- Lifetime history of schizophrenia
- DSM-IV diagnosis of alcohol or substance dependence, with the exception of nicotine dependence, within three months prior to screening
- Positive urine toxicology screen at screening (NOTE: Participants with a positive urine toxicology screen who are prescribed benzodiazepine, stimulant, or opiate medications by their physician will be permitted to enroll in the study as long as they do not meet abuse or dependence criteria for these substances)
- Female participants with a positive urine pregnancy test at screening
- Pregnancy. Females of childbearing potential must be using an effective contraceptive method (e.g., abstinence, prescription oral contraceptives, contraceptive injections, MRI-safe intrauterine device, double-barrier method, male partner sterilization)
- Any contraindications to having an MRI scan, including cardiac pacemakers, metal vascular clips or stents, artificial heart valves, certain kinds of prostheses, brain stimulator devices, implanted drug pumps, ear implants, eye implants or known metal fragments in eyes, exposure to shrapnel or metal filings (wounded in military combat, sheetmetal workers, welders, and others), transdermal drug delivery systems, and certain tattoos with metallic ink. NOTE: Participants will be screened for these conditions at screening, and will be required to fill out a standard MRI screening form at the Brain Imaging Center, which will be reviewed by an MRI technician prior to each MRI scan
- Scheduled to receive first ECT treatment on a Friday
Contacts and Locations More Information
No publications provided
| Responsible Party: | Brian P. Brennan, MD, Associate Director for Translational Neuroscience Research, Mclean Hospital |
| ClinicalTrials.gov Identifier: | NCT01557933 History of Changes |
| Other Study ID Numbers: | 2011-P-000693 |
| Study First Received: | March 9, 2012 |
| Last Updated: | November 28, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Mclean Hospital:
|
ECT Bipolar Disorder |
Additional relevant MeSH terms:
|
Bipolar Disorder Depression Depressive Disorder Affective Disorders, Psychotic |
Mood Disorders Mental Disorders Behavioral Symptoms |
ClinicalTrials.gov processed this record on June 18, 2013